Alliancebernstein L.P. maintained its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,620 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alliancebernstein L.P.’s holdings in Dynavax Technologies Corporation were worth $271,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale bought a new stake in shares of Dynavax Technologies Corporation during the first quarter valued at approximately $121,000. American International Group Inc. increased its stake in Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 1,584 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 939 shares in the last quarter. Nationwide Fund Advisors increased its stake in Dynavax Technologies Corporation by 11.2% in the first quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 2,786 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Dynavax Technologies Corporation by 30.0% in the first quarter. Wells Fargo & Company MN now owns 41,743 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 9,634 shares in the last quarter. Institutional investors and hedge funds own 57.49% of the company’s stock.

Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 0.62% during midday trading on Wednesday, reaching $16.30. The company’s stock had a trading volume of 102,355 shares. The stock has a 50 day moving average of $12.06 and a 200 day moving average of $7.35. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $19.60. The firm’s market capitalization is $892.38 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same quarter in the prior year, the company earned ($0.75) EPS. On average, equities research analysts predict that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current fiscal year.

WARNING: “Dynavax Technologies Corporation (DVAX) Position Maintained by Alliancebernstein L.P.” was posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/dynavax-technologies-corporation-dvax-position-maintained-by-alliancebernstein-l-p/1494640.html.

DVAX has been the topic of several analyst reports. Cowen and Company restated an “outperform” rating and set a $45.00 price objective on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Royal Bank Of Canada set a $7.00 price objective on Dynavax Technologies Corporation and gave the stock a “hold” rating in a report on Wednesday, July 26th. ValuEngine downgraded Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, J P Morgan Chase & Co upgraded Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $6.00 to $27.00 in a report on Monday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Dynavax Technologies Corporation has a consensus rating of “Hold” and an average price target of $23.34.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.